Compare CDMOs with sterile injectable manufacturing capabilities. Filter by container type, aseptic technology, and regulatory approvals.
283 companies listed
Sterile injectable manufacturing produces parenteral drug products -- formulations administered by injection (intravenous, subcutaneous, intramuscular, intrathecal). These products require the highest level of manufacturing control because they bypass the body's natural defense barriers. Any microbial, particulate, or endotoxin contamination can be life-threatening.
The sterile injectable market is growing faster than overall pharma, driven by biologics (monoclonal antibodies, ADCs), specialty injectables (long-acting formulations, complex generics), and the shift toward self-administered subcutaneous products. Capacity remains constrained globally, with lead times of 12-24 months at many CDMOs.
United States
CD Formulation provides formulation development, analytical services, drug packaging, and pharmaceutical excipient solutions for pharmaceutical and biotechnology companies. The company offers contract manufacturing and contract research services including liposome cGMP manufacturing, accelerated stability studies, and a wide range of formulation types including oral solid, injectable, and topical formulations. They also supply pharmaceutical excipients and active pharmaceutical ingredients.
Belgium
Cenexi is a Belgian/French CDMO specializing in sterile products, biological and injectable pharmaceutical manufacturing. The company operates four manufacturing sites in Europe, including sites in Fontenay-sous-Bois and Herouville-Saint-Clair (France), Osny (France, for highly active solid pharmaceutical forms), and Belgium. Cenexi offers services from development to commercial production for pre-filled syringes, vials, lyophilized products, tablets, capsules, and syrups, with FDA-registered manufacturing operations.
Our AI Matchmaker analyzes your project requirements and matches you with qualified manufacturing partners. Free for buyers.